Effects of losartan on the treatment of posttransplant erythrocytosis.
Erythrocytosis is a relatively common complication of renal transplantation. Recent observations indicate that angiotensin-converting enzyme inhibitors correct renal transplant erythrocytosis. Other drugs to inhibit the renin-angiotensin system have been developed recently. The newest of these is losartan, a specific antagonist of the angiotensin II type I receptor. We report three patients in which the use of losartan controlled posttransplant erythrocytosis. Our findings suggest that losartan can be effective and safe in the treatment of posttransplant erythrocytosis.
Department of Nephrology, Hospital Ntra. Sra. de Candelaria, S/C de Tenerife, Spain.
J F
JF
Navarro
J
J
García
M
M
Macía
C
C
Mora
J
J
Chahin
E
E
Gallego
M L
ML
Méndez
N
N
del Castillo
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D011086:Polycythemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D000804:Angiotensin II; D019808:Losartan